

1 April 2026

Manufacturing Agreement - Aurora Cannabis – Supplementary Information

Australian Bioxyne Limited (ASX: BXN) (“Bioxyne” or “the Company”), as requested by the ASX provides the following supplementary information in relation to the agreement signed with Aurora Cannabis Inc. (**Nasdaq/ TSX: ACB**)

1. *The indicative effect of this agreement on revenues based on indicative pricing and any minimum volumes agreed to between parties.*

The agreement with Aurora covers the full breadth of the products produced by BXN and Purchase orders have been received to date for 2 product skus of over 5000 sublingual oil products and over 20,000 vape products for delivery into Australia and the UK Market. In addition to these products, purchase orders have been received for 2 x Pastille / gummie skus. It is expected that this production relationship will result in in excess of \$3 to \$5m in production over the next 12 months as the volume and scope of production grows.

2. *If there are any minimum quantities for manufacture, disclosure of those quantities.*

Normal production minimum order quantities apply to all purchase orders received by BXN.

3. *Any other material terms that may be relevant for the market to assess the financial impact of this agreement to the company’s revenues.*

All Purchase orders are placed with a deposit with the remainder payable upon QA release, prior to dispatch.

This agreement does not change the market guidance provided on 26 February 2026.

Approved by the Board of Bioxyne Limited for release to the ASX.

For further information, please contact:

Bioxyne Limited
Sam Watson
Chief Executive Officer
info@bioxyne.com

NWR Communications
Melissa Tempra
Media & Investor Relations
melissa@nwrcommunications.com.au



About Bioxyne Ltd.

Bioxyne Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company's corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, lifestyle products, functional mushrooms and nootropics, and prescription medicines in Australia.
- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe.
- c) Contract / white label manufacture of consumer health products for brands in Japan, UK and Europe in company-owned facilities.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®
 - United Kingdom: drwatsoncbd.com
 - Japan: nolcbn.com
 - UK / EU: breathelifesciences.com
- f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

Corporate: bioxyne.com

Australia: bls.com.au

International: breathelifesciences.com



About Aurora

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. The company also holds a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.

Learn more at www.auroramj.com and follow us on [X](#) and [LinkedIn](#).

Aurora's common shares trade on the **NASDAQ** and **TSX** under the symbol "**ACB**".

Contact: Michelle Lefler | VP, Communications & PR | media@auroramj.com | For Investors: ICR, Inc. | aurora@icrinc.com